CLDX Celldex Therapeutics, Inc.
$36.90▼ -3.15%
Healthcare
Other
After hours
$36.90▲ +0.00%
Sep 11, 7:30 PM ET
Volume 1.03M
Avg Volume (10D) 579.5K
Key Metrics & Fundamentals
Market Cap
$2.90B
P/E Ratio
–
Div Yield
–%
52W Range
22.10 - 45.14
% vs 50 MA
-2.63%
% vs 200 MA
19.95%
RSI-14
40.2
MACD Histogram
-0.3900
Beta (1Y vs SPY)
1.29
Free Cash Flow
-$60.59M
Gross Rev
$22,000
Gross Profit
$22,000
EBITDA
-$86.84M
COGS
–
Operating Exp
$80.65M
Operating Income
-$80.62M
EBIT
-$80.62M
Pretax Income
-$73.50M
Net Income
-$73.50M
EPS (Diluted)
-0.94
Price & Volume History
Loading chart…
Recent News
Celldex to Present at Upcoming Investor Conference
GlobeNewswire · Sep 8, 2026 8:01 PM
Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter Results
Simply Wall St. · Aug 9, 2026 6:13 AM
Is Celldex Therapeutics’ (CLDX) Growing Losses With Minimal Revenue a Strategic Bet or Structural Concern?
Simply Wall St. · Aug 9, 2026 4:24 AM
Celldex Therapeutics (CLDX) Stock Trades At A Premium Despite A 102% Return
Simply Wall St. · Aug 9, 2026 2:08 AM
What Is Celldex Therapeutics (CLDX) Signaling With Its Mixed Pipeline Update?
Simply Wall St. · Aug 8, 2026 9:15 PM
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
Zacks · Aug 6, 2026 11:10 PM
Celldex: Q2 Earnings Snapshot
Associated Press · Aug 6, 2026 8:48 PM
Celldex Reports Second Quarter Financial Results and Provides Corporate Update
GlobeNewswire · Aug 6, 2026 8:01 PM
Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?
Zacks · Jul 24, 2026 1:40 PM
Celldex's Phase 3 Barzolvolimab Study in Chronic Spontaneous Urticaria in Focus After Prurigo Nodularis Exit, Morgan Stanley Says
MT Newswires · Jul 22, 2026 2:36 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See CLDX's money flow as a full page
Social Sentiment
No Reddit posts found for CLDX.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.